Πλοήγηση ανά Συγγραφέα "Vlachostergios, P. J."
-
Baseline Insulin-Like Growth Factor-I Plasma Levels, Systemic Inflammation, Weight Loss and Clinical Outcome in Metastatic Non-Small Cell Lung Cancer Patients
Vlachostergios, P. J.; Gioulbasanis, I.; Kamposioras, K.; Georgoulias, P.; Baracos, V. E.; Ghosh, S.; Maragouli, E.; Georgoulias, V.; Papandreou, C. N. (2011)Background: Cancer patients frequently suffer from weight loss and systemic inflammation in the context of advanced disease, which is related to adverse outcome. Insulin-like growth factor (IGF)-I is an anabolic molecule ... -
Bevacizumab in advanced cervical cancer
Vlachostergios, P. J.; Papandreou, C. N. (2014) -
The Bmi-1/NF-kappa B/VEGF story: another hint for proteasome involvement in glioma angiogenesis?
Vlachostergios, P. J.; Papandreou, C. N. (2013)Angiogenesis is an essential process for sustaining tumor growth, particularly in cancer cell types with rapid proliferation, including malignant glioma. Bmi-1 is a transcriptional regulator of the polycomb group involved ... -
Bortezomib Downregulates MGMT Expression in T98G Glioblastoma Cells
Vlachostergios, P. J.; Hatzidaki, E.; Stathakis, N. E.; Koukoulis, G. K.; Papandreou, C. N. (2013)The efficacy of treatment for glioblastoma multiforme is currently limited by the development of resistance, particularly, but not exclusively, due to the expression of the DNA repair enzyme O6-methylguanine methyltransferase ... -
Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner
Vlachostergios, P. J.; Hatzidaki, E.; Befani, C. D.; Liakos, P.; Papandreou, C. N. (2013)Development of drug resistance after standard chemotherapy for glioblastoma multiforme (GBM) with temozolomide (TMZ) is associated with poor prognosis of GBM patients and is at least partially mediated by a direct DNA ... -
Bortezomib represses HIF-1 alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells
Befani, C. D.; Vlachostergios, P. J.; Hatzidaki, E.; Patrikidou, A.; Bonanou, S.; Simos, G.; Papandreou, C. N.; Liakos, P. (2012)Bortezomib represents the first proteasome inhibitor (PI) with demonstrated antitumor activity in the clinical setting, particularly for treatment of hematological malignancies. At the preclinical level, its action is shown ... -
Bortezomib represses HIF-1 alpha protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells (vol 90, pg 45, 2012)
Befani, C. D.; Vlachostergios, P. J.; Hatzidaki, E.; Patrikidou, A.; Bonanou, S.; Simos, G.; Papandreou, C. N.; Liakos, P. (2013) -
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells
Tsapakidis, K.; Vlachostergios, P. J.; Voutsadakis, I. A.; Befani, C. D.; Patrikidou, A.; Hatzidaki, E.; Daliani, D. D.; Moutzouris, G.; Liakos, P.; Papandreou, C. N. (2012)Objectives: Neuropeptides are important signal initiators in advanced prostate cancer, partially acting through activation of nuclear factor kappa B. Central to nuclear factor kappa B regulation is the ubiquitin-proteasome ... -
CD10 Is Inversely Associated with Nuclear Factor-Kappa B and Predicts Biochemical Recurrence after Radical Prostatectomy
Voutsadakis, I. A.; Vlachostergios, P. J.; Daliani, D. D.; Karasavvidou, F.; Kakkas, G.; Moutzouris, G.; Melekos, M. D.; Papandreou, C. N. (2012)Introduction: The cell surface endopeptidase CD10 (neutral endopeptidase) and nuclear factor-kappa B (NF-kappa B) have been independently associated with prostate cancer (PC) progression. We investigated the correlations ... -
DNA repair and the ubiquitin-proteasome system: molecular insights into a clinically relevant association
Vlachostergios, P. J.; Patrikidou, A.; Daliani, D. D.; Papandreou, C. N. (2010) -
Efficacy of low dose temozolomide in combination with bortezomib in U87 glioma cells: a flow cytometric analysis
Vlachostergios, P. J.; Papandreou, C. N. (2015)Introduction: Maximizing responses of malignant gliomas is hampered by resistance to temozolomide (TMZ). Increasing efficacy but not toxicity is a key issue when testing drug combinations. The antimyeloma agent bortezomib ... -
Endothelin-1 (ET-1) and nuclear factor-kappa B (NF-kappa B) are directly interrelated and predict biochemical recurrence of hormone naive prostate cancer after radical prostatectomy
Vlachostergios, P. J.; Kakkas, G.; Moutzouris, G.; Karasavvidou, F.; Kapatou, K.; Daliani, D. D.; Melekos, M.; Papandreou, C. N. (2012) -
Evidence of Association Between Methylenetetrahydrofolate Reductase Gene and Susceptibility to Breast Cancer: A Candidate-Gene Association Study in a South-Eastern European Population
Papandreou, C. N.; Doxani, C.; Zdoukopoulos, N.; Vlachostergios, P. J.; Hatzidaki, E.; Bakalos, G.; Ziogas, D. C.; Koufakis, T.; Zintzaras, E. (2012)The methylenetetrahydrofolate reductase (MTHFR) gene has been proposed as a candidate gene for breast cancer (BC). However, the specific role of MTHFR polymorphisms and haplotypes has not been fully clarified and replicated. ... -
The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer
Gioulbasanis, I.; Pallis, A.; Vlachostergios, P. J.; Xyrafas, A.; Giannousi, Z.; Perdikouri, I. E.; Makridou, M.; Kakalou, D.; Georgoulias, V. (2012)Purpose: Lung cancer is the most common cause of cancer death. A cumulative prognostic score based on C-reactive protein and albumin, termed the Glasgow Prognostic Score (GPS), indicates the presence of systemic inflammatory ... -
Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma
Vlachostergios, P. J.; Voutsadakis, I. A.; Papandreou, C. N. (2013)The 26S proteasome constitutes an essential degradation apparatus involved in the consistent recycling of misfolded and damaged proteins inside cells. The aberrant activation of the proteasome has been widely observed in ... -
MGMT repletion after treatment of glioblastoma cells with temozolomide and O6-benzylguanine implicates NF kappa B and mutant p53
Vlachostergios, P. J.; Hatzidaki, E.; Papandreou, C. N. (2013)The DNA repair enzyme O6-methylguanine methyltransferase (MGMT) is a major determinant of glioma resistance to alkylating agents. Several strategies have been used to induce sensitization to alkylator-based treatments, ... -
NEUTRAL ENDOPEPTIDASE (NEP) AND ENDOTHELIN 1 (ET-1) ARE INVERSELY EXPRESSED IN HORMONE-NAIVE PROSTATE CANCER AND ARE PREDICTORS OF BIOCHEMICAL FAILURE FROM RADICAL PROSTATECTOMY
Vlachostergios, P. J.; Patrikidou, A.; Kakkas, G.; Moutzouris, G.; Voutsadakis, I. A.; Karasavvidou, F.; Daliani, D. D.; Koukoulis, G.; Melekos, M. D.; Papandreou, C. N. (2010) -
p53 and Cyclooxygenase-2 Expression are Directly Associated with Cyclin D1 Expression in Radical Prostatectomy Specimens of Patients with Hormone-Naive Prostate Cancer
Vlachostergios, P. J.; Karasavvidou, F.; Patrikidou, A.; Voutsadakis, I. A.; Kakkas, G.; Moutzouris, G.; Zintzaras, E.; Daliani, D. D.; Melekos, M. D.; Papandreou, C. N. (2012)Prostate cancer (PCa) is a potentially curable disease when diagnosed in early stages and subsequently treated with radical prostatectomy (RP). However, a significant proportion of patients tend to relapse early, with the ... -
Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer
Vlachostergios, P. J.; Gioulbasanis, I.; Ghosh, S.; Tsatsanis, C.; Papatsibas, G.; Xyrafas, A.; Hatzidaki, E.; Vasiliou, C.; Kamposioras, K.; Agelaki, S.; Margioris, A. N.; Nasi, D.; Georgoulias, V.; Papandreou, C. N. (2013)Cancer patients usually develop malnutrition which may alter their innate immune system integrity. The aim of this study was to investigate the clinical relevance of chemokine response after lipopolysaccharide (LPS)-stimulation ... -
Pulmonary and cutaneous nodules in an immunocompromised patient
Vlachostergios, P. J.; Karamagkiolis, S.; Karamitsos, K. (2011)